Receiver operating characteristic analysis: Calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 352-356

  Klingenstein, Annemarie ^a   Haritoglou, Ingrid ^a   Schaumberger, Markus M ^a   Nentwich, Martin M ^a   Hein, Rüdiger ^b   Schaller, Ulrich C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

enzyme linked immunosorbent assay; melanoma inhibitory activity; metastases; serological marker; uveal melanoma

Indexed keywords

BIOLOGICAL MARKER; MELANOMA INHIBITORY ACTIVITY PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GERMANY; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 79960709707     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328347105e     Document Type: Article

References (24)

1. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005; 140:612-617.
2. Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46:133-149. (Pubitemid 44124236)
3. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13:1171-1178. (Pubitemid 46424057)
4. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. A meta-analysis of 5-year mortality rates following enucleation. 1966 through 1988. Arch Ophthalmol 1992; 110:245-250.
5. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993; 71:2299-2305. (Pubitemid 23087771)
6. Peters S, Voelter V, Zografos L, Pampallona S, Peters S, Halkic N, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578-583.
7. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005; 15: 205-207. (Pubitemid 40839469)
8. Schuster R, Lindner M, Wacker F, Krössin M, Bechrakis NE, Foerster MH, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20:191-196.
9. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006; 46:151-166. (Pubitemid 44124237)
10. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007; 27:1897-1900. (Pubitemid 46954694)
11. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 2009; 223:2239-2243.
12. Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A, Mueller AJ. 'Melanoma inhibitory activity' (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefe's Arch Clin Exp Ophthalmol 2005; 243:1161-1166. (Pubitemid 43124169)
13. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 2002; 12:593-599. (Pubitemid 36042746)
14. Reiniger IW, Wolf A, Welge-Lüssen U, Mueller AJ, Kampik A, Schaller UC. Osteopontin as a serological marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 2007; 143:705-707. (Pubitemid 46452513)
15. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-298. (Pubitemid 9075026)
16. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000; 45:23-41. (Pubitemid 30308338)
17. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57:3149-3153. (Pubitemid 27351728)
18. Van Erkel AR, Pattynama PM. Receiver operating characteristic (ROC) analysis: Basic principles and applications in radiology. Eur J Radiol 1998; 27:88-94. (Pubitemid 28234366)
19. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240:1285-1293.
20. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004; 22:2438-2444. (Pubitemid 41115402)
21. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci 2004; 45:1-6. (Pubitemid 38055660)
22. Kaiserman I, Amer R, Pe'er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 2004; 137:236-243. (Pubitemid 38220994)
23. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-1225. (Pubitemid 26131850)
24. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44:1008-1011. (Pubitemid 36297813)